9th Sep 2013 09:02
LONDON (Alliance News) - Clinigen Group PLC Monday said it had signed a deal to exclusively manage an access program to supply Eisai's anti-epilepsy drug Fycompa in Germany.
The deal comes after commercial distribution of Fycompa in Germany was temporarily suspended, Clinigen said.
"This program represents the addition of another major pharmaceutical company to our expanding client base," Clinigen Chief Executive Peter George said in a statement.
Clinigen's shares were up 1.1% at 376.539 pence Monday morning.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L